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Introduction
Cholinesterase inhibitors are widely used in the
symptomatic treatment of Alzheimer’s disease (AD)
in clinical practice. They act by inhibiting one or
both of the enzymes responsible for the hydrolysis
of acetylcholine in the synaptic cleft [acetylcholines-
terase (AChE) and butyrylcholinesterase (BuChE)],
thereby increasing available acetylcholine levels and
improving neurotransmission. Three cholinesterase
inhibitors are commonly used to treat cognitive
symptoms in mild-to-moderate AD: rivastigmine
(Exelon
 ; Novartis, Basel, Switzerland), donepezil
(Aricept
 ; Pﬁzer, New York, NY, USA) and galanta-
mine (Reminyl
 ⁄Razadyne
 ; Johnson & Johnson,
New Brunswick, NJ, USA).
Some cholinesterase inhibitors exhibit a dose–
response relationship, with higher drug doses corre-
lating with greater enzyme inhibition (1). As AD is a
progressive, neurodegenerative disorder where
patients deteriorate over time, one goal in clinical
practice is to achieve higher doses that maximise the
effectiveness of treatment. However, the incidence of
adverse events (AEs) associated with oral cholinester-
ase inhibitors, particularly nausea and vomiting, also
increases with higher doses (2). Consequently,
achieving and maintaining high therapeutic doses in
clinical practice may be difﬁcult.
Rivastigmine is a pseudo-irreversible inhibitor of
both AChE and BuChE and has been shown in a
number of clinical trials to be efﬁcacious in AD (3–5).
Unlike other cholinesterase inhibitors that are only
available in oral formulations, a novel transdermal
rivastigmine patch has been developed and approved
for the treatment of mild-to-moderate AD in many
countries worldwide, including the USA, Latin
America, Europe and Asia. The pharmacokinetic
rationale for the patch suggests that it may provide
clinical effectiveness with a more favourable tolerabil-
ity proﬁle, allowing a simple one-step titration to the
recommended dose. The patch design itself may prove
more convenient, easier to use and provide visual
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thus potentially improving compliance (6,7).
The rivastigmine patch is the ﬁrst transdermal
treatment for AD, and another cholinesterase inhibi-
tor is also being developed to deliver medication
transdermally (8). Patches may have inherent advan-
tages over conventional oral formulations, and it is
interesting to consider how they might change the
treatment paradigm. This article reviews the clinical
features of patch therapy for dementia, compared
with conventional oral administration.
Challenges with orally administered
cholinesterase inhibitors
When a drug is administered orally, it is absorbed
through the gastrointestinal wall, and plasma drug
levels rise rapidly to their peak level (Cmax). Drug
plasma levels then fall until the next dose is adminis-
tered, at which point the plasma levels are at their
lowest (Cmin). Larger and more frequent plasma ﬂuc-
tuations are associated with an increased incidence of
cholinergically mediated side effects, particularly gas-
trointestinal AEs such as nausea and vomiting (2).
By reducing Cmax and slowing the time that it takes
to reach Cmax (tmax), the potential for these AEs may
be reduced (2).
Between Cmax and Cmin lies an optimal therapeutic
window, which, because of the dose–response rela-
tionship associated with cholinesterase inhibitors,
offers the best balance between efﬁcacy and the
potential for side effects. The ideal pharmacokinetic
proﬁle for a cholinesterase inhibitor treatment would
be a smooth, steady delivery of the drug, maintaining
plasma levels within this window.
One way this may be achieved is by modifying the
dosing regimen, as demonstrated in a recent, rando-
mised, placebo-controlled trial comparing the efﬁcacy
and safety of twice daily (bid) vs. three times daily
(tid) rivastigmine capsules (9). By administering the
same target daily dose of rivastigmine in smaller, more
frequent doses, the Cmax and peak–trough difference
in plasma concentration were reduced. This was
reﬂected in a lower discontinuation rate because of
AEs in the tid group compared with the bid group
(10.6% and 16.7%, respectively; placebo = 9.0%).
Furthermore, a greater proportion of subjects reached
the target dose (12 mg⁄day) in the tid group vs. the
bid group (60% vs. 43% after the 12-week titration
phase) and larger treatment effects were observed for
the primary efﬁcacy variables. After 26 weeks, a 0.2-
point improvement was observed in the tid group on
the cognitive subscale of the Alzheimer’s Disease
Assessment Scale, and a 0.1-point improvement on the
Clinician’s Interview-Based Impression of Change plus
Caregiver Input (vs. a 1.2- and 0.1-point deterioration
in the bid group respectively) (9). This suggests that a
smoother pharmacokinetic proﬁle is associated not
only with improved tolerability, but may also allow
more patients to reach higher doses, potentially
improving treatment effectiveness.
An alternative strategy for reducing Cmax and pro-
longing tmax (while maintaining the overall drug expo-
sure) is co-administration of rivastigmine with food.
This can delay the absorption of the drug from the
gut. However, the effect is heavily dependent on the
type of food involved, and as such can be unpredict-
able. Furthermore, simply reducing Cmax alone does
not necessarily improve tolerability. A study evaluating
the safety and tolerability of an extended-release (ER)
formulation of galantamine showed no advantage of
ER capsules vs. conventional capsules (10). The Cmax
was reduced with the ER formulation. However, the
initial rate of absorption was similar to that seen with
conventional capsules, resulting in a similar peak–
trough difference of  40 ng⁄ml over 24 h. This was
reﬂected in a similar incidence of cholinergic AEs (10).
The development of a transdermal patch was therefore
favoured over an ER formulation for rivastigmine.
By providing smooth and continuous delivery of
rivastigmine through the skin and directly into the
bloodstream, a transdermal patch would lower Cmax
and prolong tmax while maintaining drug exposure. As
discussed, this could potentially improve tolerability,
allow patients easier access to therapeutic doses and
optimise the effectiveness of treatment (6). The dosing
frequency study, combined with improved patch
technology, therefore provided the rationale for the
development of a rivastigmine transdermal patch for
the treatment of AD.
Pharmacokinetic proﬁle of the
rivastigmine patch
Multilayer matrix patch design
Unlike early transdermal patches, which utilised a
‘reservoir’ of the drug dissolved in an adjunct to
facilitate drug absorption through the skin (usually
alcohol), the rivastigmine transdermal patch uses a
modern matrix design. This combines the drug,
antioxidants, a polymer mixture that controls the
drug delivery rate, and a silicone matrix adhesive to
make a single ‘polymeric matrix’ layer. This allows
smooth, controlled delivery of the drug via diffusion
from the matrix and enables the patches to be kept
small, thin and discreet (11).
Absorption
The efﬁciency and rate of absorption of a drug
through the skin is dependent on many biological
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pass rapidly through the stratum corneum via the
lipid-rich intercellular space, whereas hydrophilic
agents must dissolve and diffuse through cellular-
bound water into the bloodstream (11). The molecu-
lar size of the agent is also an important factor in
determining the suitability for transdermal delivery;
smaller molecules tend to be absorbed faster than
larger molecules, with very large molecules such as
insulin (5808 Da) being too large to pass through
the skin. It has been suggested that any compound
with a molecular weight above 500 Da is likely to be
unsuitable for transdermal delivery (12). As a small
( 250 Da), lipophilic and hydrophilic molecule, riv-
astigmine is chemically well-suited to transdermal
delivery.
To provide the necessary concentration gradient
to drive the diffusion process through the skin, all
rivastigmine transdermal patches are loaded with
a greater amount of rivastigmine than will be
absorbed into the bloodstream. In a study of 51
AD patients, the average amount of rivastigmine
absorbed from a patch over a 24-h application
period was approximately 50% of the total loading
dose. The 5 cm
2 patch released 4.6 mg (51% of
9 mg), the 10 cm
2 patch released 9.5 mg (53% of
18 mg), the 15 cm
2 patch released 13.3 mg (49%
of 27 mg) and the 20 cm
2 patch released 17.4 mg
(48% of 36 mg) (13). Absorption of any remaining
rivastigmine following the 24-h application period
was shown to occur very slowly (13). Patients should
therefore not be at risk of toxic exposure should
a new patch be mistakenly applied without prior
removal of the previous patch. Once removed, the
short elimination half-life (t1 ⁄ 2) of rivastigmine (cap-
sule doses = 1.3–1.9 h; 17.4 mg⁄24 h patch = 3.4 h)
(13) ensures the rapid reduction of drug levels in
the plasma. As a result, even with the continuous
delivery provided with the rivastigmine patch, there
is little potential for accumulation in the body.
Daily pharmacokinetic proﬁle
The results from an open-label study of 51
AD patients randomised to rivastigmine patch
(4.6–17.4 mg⁄24 h; 5–20 cm
2), or capsules (3–12 mg⁄
day), were used in a compartmental analysis to
model rivastigmine plasma levels over a 24-h applica-
tion period (Figure 1). Drug exposure was assessed
by measuring the area under the curve over a 24-h
treatment period (AUC24 h), using a speciﬁc power
model (14).
The 4.6 mg⁄24 h patch was shown to provide
comparable rivastigmine exposure to a 6 mg⁄day
capsule dose [AUC24 h = 64 and 60 ngÆh⁄ml (p = ns)
respectively] and the 9.5 mg⁄24 h patch comparable
exposure to the highest recommended capsule dose
[12 mg⁄day; AUC24 h = 166 and 207 ngÆh⁄ml (p =
ns) respectively]. The 13.3 mg⁄24 h and 17.4 mg⁄
24 h patches provide greater rivastigmine exposure
than any approved oral dose (AUC24 h = 312 and
474 ngÆh⁄ml).
All patch doses provided smoother and more con-
tinuous delivery of rivastigmine than oral adminis-
tration (Figure 1) (15). Both the 4.6 mg⁄24 h and
9.5 mg⁄24 h patches provided signiﬁcantly lower riv-
astigmine Cmax and longer tmax (all p < 0.001) vs.
capsule doses of comparable exposure: 6 mg⁄day
(Cmax 3.3 vs. 6.8 ng⁄ml; tmax 8.2 vs. 1.2 h) and
12 mg⁄day (Cmax 8.7 vs. 21.6 ng⁄ml; tmax 8.1 vs.
1.4 h) respectively (15). These results are supported
by a separate, non-compartmental, non-adjusted
analysis of the same data (13). Similarly, a recent
study comparing rivastigmine oral solution
(3 mg⁄day) with the 9.5 mg⁄24 h patch showed the
patch to have a 20% lower Cmax and 14-times longer
tmax, with ﬁve-times the drug exposure of the oral
solution (Cmax = 5.8 vs. 7.6 ng⁄ml; tmax = 14.1 vs.
1.0 h; AUC¥ = 118 vs. 23 ngÆh⁄ml respectively) (16).
By providing similar drug exposure with a lower
maximum concentration and slower absorption rate,
the rivastigmine patch may provide similar efﬁcacy
to orally administered rivastigmine, with a more
favourable tolerability proﬁle.
Enzyme inhibition
Rivastigmine is distinct from other available cholin-
esterase inhibitors (donepezil and galantamine), in
that it is a pseudo-irreversible inhibitor of both
AChE and BuChE, rather than a rapidly reversible
inhibitor of AChE alone. The inhibition of these
enzymes in vivo was expected to mirror the plasma
concentration proﬁles, with the rivastigmine patch
providing steadier and more consistent inhibition
than that of oral rivastigmine. AChE has an extre-
mely low concentration in the plasma, and as such
the enzymatic activity cannot be measured. However,
as rivastigmine is a dual inhibitor, the enzymatic
activity of BuChE in the plasma may be used as a
marker of target enzyme inhibition over time.
In a pharmacokinetic study by Lefe `vre et al. (13),
a steady reduction in plasma BuChE activity was
observed following patch administration. The target
dose 9.5 mg⁄24 h patch provided maximum inhibi-
tion after  12 h and maintained this for the remain-
der of the 24-h application period. In contrast, two
distinct peak–troughs in plasma BuChE activity were
seen with capsule administration. These results indi-
cate that the inhibition of the target enzymes of riv-
astigmine follows the pharmacokinetic proﬁle closely,
with the patch providing smooth and continuous
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application period.
Application sites
The pharmacokinetic parameters of transdermal drug
delivery can vary between patch application sites.
The optimal position would offer maximum drug
exposure, be easily accessible and avoid adhesion or
tolerability issues (e.g. areas of hairy or sensitive
skin).
In a recent single-centre, single-dose, open-label,
randomised-sequence, application study in 40 healthy
men or women aged 40–80 years, the pharmacoki-
netics, adhesion and skin tolerability of the rivastig-
mine patch were assessed (17). A 9.5 mg⁄24 h
(10 cm
2) patch was applied to one of the following
ﬁve sites and worn for 24 h: upper back, chest, thigh,
abdomen and upper arm. Each participant under-
went ﬁve 24-h applications, one for each applica-
tion site, which were separated by a 72-h washout
period.
Exposure levels (AUC24 h) and Cmax were shown
to be the greatest when the patch was applied to the
chest, upper back and upper arm (Figure 2; 123, 122
and 116 ngÆh⁄ml respectively). Because of the small
molecular size and lipophilic nature of rivastigmine,
the minimal skin thickness and subcutaneous body
fat at these sites may have contributed to this ﬁnd-
ing. The degree or level of adhesion was only shown
to have a signiﬁcant effect on AUC24 h and Cmax
when the patch was applied to the chest (p = 0.014
and 0.022 respectively). At all application sites, tmax
was very slow (16–22 h) indicating smooth and con-
trolled release of rivastigmine into the bloodstream.
Erythema was the only type of skin reaction reported
during the study and was least likely to occur when
the patch was applied to the upper arm, chest and
upper back.
It is therefore recommended that the patch be
applied to clean and dry skin on the back, upper
arm or chest to obtain maximum rivastigmine expo-
sure with minimal risk of skin reactions. To further
Figure 1 Steady-state rivastigmine plasma levels for a typical patient following administration of the 9.5 mg⁄24 h
rivastigmine patch vs. 6 mg bid capsules, and the 4.6 mg⁄24 h rivastigmine patch vs. 3 mg bid capsules. The model adjusts
for body weight and gender (15)
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should be alternated daily between sites on the right
and the left side of the body.
Metabolism and bioavailability
Rivastigmine is rapidly and extensively metabolised
to the inactive NAP226-90 metabolite by its target
enzymes (AChE and BuChE), with little or no inter-
action with hepatic cytochrome P450 isoenzymes
(18). However, a small amount of ﬁrst-pass metabo-
lism of orally administered rivastigmine may still
occur via peripheral cholinesterases in the gut. This
effect has been demonstrated in previous pharmaco-
kinetic studies by assessing the ratio of NAP226-90
to rivastigmine following transdermal patch or oral
(capsule or solution) administration (13,16). The
ratio was shown to be considerably lower following
transdermal treatment (0.60–0.72) (13,16) than both
capsule (1.10–3.15) (13) and oral solution (3.49)
(16) treatment. This indicates that rivastigmine
administered transdermally bypasses the phase I
metabolism, thereby increasing the systemic bioavail-
ability of the drug. Consequently, the 9.5 mg⁄24 h
rivastigmine patch (10 cm
2, AUC24 h = 166 ngÆh⁄ml)
may provide comparable effectiveness to the highest
doses of capsules (12 mg⁄day, AUC24 h = 207 ngÆh⁄
ml), despite having a numerically lower AUC24 h.
Clinical effects with transdermal dosing
One of the major obstacles to the effective treatment
of AD with oral cholinesterase inhibitors has been
tolerability, which can prevent many patients from
reaching efﬁcacious therapeutic doses in clinical
practice. Until recently, all cholinesterase inhibitors
were administered orally, but the newly developed
rivastigmine patch appears to overcome this tolera-
bility obstacle by employing a different dosing route
and may offer a substantial clinical advantage.
Modelling analyses adjusting for baseline demo-
graphic factors demonstrated that the 9.5 mg⁄24 h
patch (10 cm
2) provides comparable exposure, and
therefore potentially similar efﬁcacy, to the highest
doses of rivastigmine capsules (12 mg⁄day). The
pharmacokinetic proﬁle, with a reduced Cmax and
prolonged tmax, also predicts an improved tolerability
proﬁle vs. conventional rivastigmine capsule adminis-
tration. These hypotheses are supported by results
from the landmark Investigation of transDermal
Exelon in ALzheimer’s disease trial (IDEAL). This was
a randomised, double-blind, double-dummy, placebo-
controlled trial to investigate the efﬁcacy and tolera-
bility of the rivastigmine patch (4.6–17.4 mg⁄24 h)
vs. capsules (3–12 mg⁄day) in 1195 AD patients (19).
Patients randomised to patch treatment were started
on the 4.6 mg⁄24 h patch and titrated in a single step
to the recommended 9.5 mg⁄24 h patch. During the
24-h application period, patients were able to pursue
all normal activities, including washing and bathing.
The trial was also conducted in countries with varying
climates, including some hot and humid regions (e.g.
Guatemala, Venezuela).
The 9.5 mg⁄24 h patch provided similar efﬁcacy
to the highest doses of capsules (12 mg⁄day) on vari-
ous outcome measures (Table 1), with three times
fewer reports of nausea and vomiting (7.2% vs.
23.1% and 6.2% vs. 17.0% respectively; Table 1)
(19). This supports the rationale for the patch that a
smoother pharmacokinetic proﬁle would yield fewer
cholinergically mediated AEs while maintaining ther-
apeutic concentrations. Similar efﬁcacy between the
9.5 mg⁄24 h patch and 12 mg⁄day capsule groups,
despite the patch providing slightly less drug, dem-
onstrates the advantage with transdermal delivery of
the avoidance of ﬁrst pass metabolism by peripheral
cholinesterases in the gut.
The efﬁcacy of the 4.6 mg⁄24 h patch was not
assessed in the IDEAL trial, however pharmacokinetic
A
B
Figure 2 (A) Mean drug exposure (area under curve)
following a single 24-h application of the 9.5 mg⁄24 h
rivastigmine patch to the upper back, chest, abdomen,
thigh or upper arm of 40 healthy subjects.
(B) Recommended application sites
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6m g⁄day capsules (64.1 vs. 60.0 ng h⁄ml respec-
tively), which is considered an effective therapeutic
dose (3–5). Also, fewer reports of nausea and vomit-
ing were reported with the starting dose 4.6 mg⁄24 h
patch (1.9% and 0.5%, weeks 1–4), than the starting
3m g⁄day capsule dose (3.1% and 2.0%; Novartis,
data on ﬁle). Therefore, in contrast to the conven-
tional capsule regimen (16-week, four-step titration
from 3 to 12 mg⁄day), patients treated with the riv-
astigmine patch are initiated on an effective dose
with improved gastrointestinal tolerability, and can
then be titrated in a single step to the recommended
therapeutic dose (9.5 mg⁄24 h patch) after only
4 weeks.
The improved tolerability proﬁle of the patch also
suggests that it may allow patients an easier path to
higher doses, thereby enabling patients to stay on
and beneﬁt from effective treatment for longer. This
is reﬂected in the greater proportion of patients
who achieved their target therapeutic dose in the
9.5 mg⁄24 h patch group at the end of the study,
compared with the 12 mg⁄day capsule group (95.9%
vs. 64.4% respectively). Further investigations of
the efﬁcacy and safety of higher doses of rivastig-
mine (13.3 mg⁄24 h, AUC24 h = 312 ngÆh⁄ml) are
ongoing.
Transdermal administration typically carries with
it the risk of additional AEs not associated with oral
administration, such as application site skin irritation
and sleep disturbances (because of 24-h drug
delivery). However, during the IDEAL trial no new
safety issues were reported. In addition, the adhesion
of the patch was very good, despite patients being
permitted to pursue all normal daily activities
including bathing and swimming. Skin irritation was
actively assessed by the investigator or caregiver, yet
most patients experienced ‘no, slight, or mild’ skin
irritation (90–98% across all patch doses), with
< 2.5% of patients in any treatment group discon-
tinuing because of adverse skin reactions (19).
Clinical experience suggests that the most common
form of skin irritation is erythema caused by removal
of the patch, which normally resolves after a short
period of time (20). In the IDEAL trial, the signs or
symptoms that were most frequently reported as
moderate or severe were erythema (redness; 8% for
the 9.5 mg⁄24 h rivastigmine patch, up to 4% for
placebo) and pruritus (itching; 7% for the
9.5 mg⁄24 h rivastigmine patch, up to 3% for pla-
cebo) (19). As stated previously (and in addition to
the lower back), Lefe `vre et al. (17) demonstrated that
the application of the rivastigmine transdermal patch
to the upper arm, chest or upper back is least likely
Table 1 Results from a randomised, double-blind, placebo-controlled trial of 1195 patients with mild-to-moderate AD:
mean changes from baseline at week 24 for primary and secondary outcome measures, by double-blind treatment
group (9.5 mg⁄24 h rivastigmine patch, capsule and placebo groups), together with incidences of nausea and vomiting
(19)
Mean 24-week change from baseline
9.5 mg/24 h patch Capsule (3–12 mg/day) Placebo
Primary outcomes
ADAS-cog )0.6** )0.6** 1.0
ADCS-CGIC 3.9** 3.9** 4.2
Secondary outcomes
MMSE 1.1** 0.8** 0.0
ADCS-ADL )0.1** )0.5* )2.3
Trail making test part A )12.3*** )9.8*** 7.7
Adverse events, %
Nausea 7.2 23.1*** 5.0
Vomiting 6.2 17.0*** 3.3
ITT-LOCF population. MMSE, Mini-Mental State Examination; ADAS-cog, cognitive subscale of the Alzheimer’s Disease Assessment
Scale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living scale; ADCS-CGIC, Alzheimer’s Disease Cooperative
Study Clinical Global Impression of Change. Negative change scores on ADAS-cog and Trail Making Test part A indicate improvement.
Negative change scores on MMSE and ADCS-ADL indicate deterioration. ADCS-CGIC is scored as a judgement of change, with 4.0
indicating no change, < 4.0 indicating improvement and > 4.0 indicating deterioration. *p £ 0.05, **p £ 0.01, ***p £ 0.001 vs. pla-
cebo; p-values for ADAS-cog, ADCS-ADL and Trail Making Test part A are derived from two-way ANCOVA (explanatory variables: treat-
ment, country and baseline scores), whereas p-values for ADCS-CGIC and MMSE are derived from the CMH van Elteren test using
modiﬁed ridit scores with country as the stratiﬁcation variable.
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tion of the application site is recommended in the
product label to minimise skin irritation, avoiding
the exact same spot for at least 14 days (although
consecutive patches may be applied to the same ana-
tomical site).
Conclusion
Overall, current clinical data support the pharmaco-
kinetic rationale of the rivastigmine patch, demon-
strating that the smooth continuous drug delivery
provided by transdermal administration translates
into comparable efﬁcacy with an improved tolerabil-
ity proﬁle vs. oral administration. This drug adminis-
tration route could therefore allow optimal
therapeutic dosing, potentially further improving the
effectiveness of treatment. The rivastigmine patch
may be the optimal way to deliver rivastigmine to
treat AD, and may be the ﬁrst of several transdermal
options in the ‘next generation’ of cholinesterase
inhibitor formulations.
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